Literature DB >> 16111664

Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.

Birgit Jaschke1, Cornelia Michaelis, Stefan Milz, Michael Vogeser, Thomas Mund, Ludger Hengst, Adnan Kastrati, Albert Schömig, Rainer Wessely.   

Abstract

OBJECTIVE: Therapeutic strategies to provide local inhibition of mitogen mediated proliferation and migration of human coronary artery smooth muscle cells (CASMC) by means of drug-eluting stents have been shown to enable effective limitation of neointimal hyperplasia. However, currently available drug-eluting stents utilize compounds that may also adversely affect endothelial regrowth, thus possibly precipitating subsequent cardiac events. Accordingly, identification of compounds that differentially inhibit smooth muscle and endothelial cell migration and proliferation could be of substantial clinical usefulness. METHODS AND
RESULTS: In addition to lipid lowering, statins are known to display auxiliary pleiotropic activities. The purpose of this study was to evaluate the effect of local administration of cerivastatin on proliferation, migration and cytotoxicity of CASMC as well as coronary artery endothelial cells (CAEC) and to evaluate the effect of cerivastatin-coated stents on the inhibition of neointima formation as well as endothelial regrowth within the stented vessel. Cerivastatin displayed a differential effect on CASMC as compared to CAEC with regard to proliferation and migration; both were more profoundly inhibited in CASMC. Appreciable cytotoxicity and pro-apoptotic effects were low in both cell lines at therapeutic concentrations. Cerivastatin-elution led to significant inhibition of neointima formation in the rat carotid stent model, endothelial coverage of in-stent vascular tissue was similar with control and cerivastatin-eluting stents.
CONCLUSIONS: As proof of principle, our study provides evidence that local application of a HMG-CoA reductase inhibitor on a drug-eluting stent platform can efficiently limit neointima formation. Consequently, these compounds warrant further clinical evaluation to confirm this finding. Our data further suggest that the anti-restenotic effect of local statin administration might be associated with a more protective interaction with the endothelium than that observed with compounds currently employed on drug-eluting stents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111664     DOI: 10.1016/j.cardiores.2005.06.029

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  12 in total

1.  Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost.

Authors:  Paola Castagnino; Devashish Kothapalli; Elizabeth A Hawthorne; Tina Xu; Richard K Assoian
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-05-10       Impact factor: 3.072

Review 2.  New drug-eluting stent concepts.

Authors:  Rainer Wessely
Journal:  Nat Rev Cardiol       Date:  2010-03-02       Impact factor: 32.419

3.  Smooth Muscle Cell Proangiogenic Phenotype Induced by Cyclopentenyl Cytosine Promotes Endothelial Cell Proliferation and Migration.

Authors:  Rui Tang; Gui Zhang; Shi-You Chen
Journal:  J Biol Chem       Date:  2016-11-07       Impact factor: 5.157

Review 4.  Translational research on novel drug-eluting stents in percutaneous coronary intervention.

Authors:  Yaling Han; Kai Xu; Chenghui Yan
Journal:  Front Med       Date:  2011-12-27       Impact factor: 4.592

Review 5.  Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury.

Authors:  Austin I McDonald; M Luisa Iruela-Arispe
Journal:  Vascul Pharmacol       Date:  2015-06-18       Impact factor: 5.773

Review 6.  Factors that affect mass transport from drug eluting stents into the artery wall.

Authors:  Barry M O'Connell; Tim M McGloughlin; Michael T Walsh
Journal:  Biomed Eng Online       Date:  2010-03-09       Impact factor: 2.819

7.  Drug packaging and delivery using perfluorocarbon nanoparticles for targeted inhibition of vascular smooth muscle cells.

Authors:  Zhao-xiong Zhou; Bai-gen Zhang; Hao Zhang; Xiao-zhong Huang; Ya-li Hu; Li Sun; Xiao-min Wang; Ji-wei Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

8.  Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries.

Authors:  Ilia Fishbein; Ivan Alferiev; Marina Bakay; Stanley J Stachelek; Peter Sobolewski; Meizan Lai; Hoon Choi; I-W Chen; Robert J Levy
Journal:  Circulation       Date:  2008-04-14       Impact factor: 29.690

9.  Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway.

Authors:  Brian K Stansfield; Waylan K Bessler; Raghuveer Mali; Julie A Mund; Brandon Downing; Fang Li; Kara N Sarchet; Matthew R DiStasi; Simon J Conway; Reuben Kapur; David A Ingram
Journal:  Hum Mol Genet       Date:  2012-11-29       Impact factor: 6.150

Review 10.  Established and emerging approaches for the management of dyslipidaemia.

Authors:  Giuseppe Danilo Norata
Journal:  Scientifica (Cairo)       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.